Neogen Q4 Revenue $225.3M, Core Growth 4.3%; FY27 Guidance
Neogen Corporation reported fiscal fourth quarter 2026 revenue of $225.3 million, a slight decrease of 0.1% but with core growth of 4.3%. Full fiscal year 2026 revenue was $870.4 million, down 2.7% with 1.9% core growth. The company achieved a net loss of $(11.3) million for the quarter, but an Adjusted Net Income of $18.7 million and Adjusted EBITDA of $45.4 million. Neogen also provided FY27 financial guidance, projecting revenue between $880 million and $885 million, and is on track with its Petrifilm manufacturing transition and the divestiture of its Genomics business.
Key Highlights
- Q4 FY26 Revenue: $225.3 million, (0.1%) growth, 4.3% core growth.
- Full FY26 Revenue: $870.4 million, (2.7%) growth, 1.9% core growth.
- Q4 Food Safety Core Growth: 5.8%, highest since FY23.
- Q4 Animal Safety Core Growth: 0.5%, sequential revenue up 7%.
- Q4 Net Loss: $(11.3) million; Adjusted Net Income: $18.7 million.
- Q4 Adjusted EBITDA: $45.4 million, 20.2% margin.
- FY27 Revenue Guidance: $880-$885 million.
- Genomics business divestiture to Zoetis Inc. for $160 million is ongoing.
Price Impact
More from NEOG
NEOGEN to Divest Genomics Business to Zoetis for $160M
NEOGEN CORP Files Q3 2026 Quarterly Report, Reports 217.7M Shares Outstanding
Neogen Reports Q3 FY2026 Revenue of $211.2M, GAAP EPS of $(0.08) Amidst Animal Safety Supplier Challenges